biostudies-literatureUnknown18Schade P<h4>Background</h4>Complete vaccination coverage is recommended by multiple sclerosis (MS) societies for patients with multiple sclerosis (pwMS) to mitigate infection risks associated with disease-modifying therapies (DMTs).<h4>Objectives</h4>To analyze vaccination coverage and its determinants in pwMS compared to healthy controls, considering vaccination hesitancy, MS-specific vaccination beliefs, trust in information sources, and the role of general practitioners (GPs).<h4>Methods</h4>This cross-sectional multicenter observational study was conducted in six German MS centers. The primary endpoint was a vaccination index (VI) comprising eight standard vaccinations (range 0-1, with higher VI indicating better vaccination coverage). Secondary endpoints included validated measures of generalTherapeutic advances in neurological disorders17562864241309806https://www.ebi.ac.uk/biostudies/studies/S-EPMC11760134biostudies-literatureVaccination coverage and its determinants in patients with multiple sclerosis-a multicenter cross-sectional study.PMC11760134Richter SHellwig KWagner BGeis CElias-Hamp BBecker VRakers FPelea TFranken PSchwab MSchade PSteinle JNguyen HAMerkelbach SfalseVaccination coverage and its determinants in patients with multiple sclerosis-a multicenter cross-sectional study.<h4>Background</h4>Complete vaccination coverage is recommended by multiple sclerosis (MS) societies for patients with multiple sclerosis (pwMS) to mitigate infection risks associated with disease-modifying therapies (DMTs).<h4>Objectives</h4>To analyze vaccination coverage and its determinants in pwMS compared to healthy controls, considering vaccination hesitancy, MS-specific vaccination beliefs, trust in information sources, and the role of general practitioners (GPs).<h4>Methods</h4>This cross-sectional multicenter observational study was conducted in six German MS centers. The primary endpoint was a vaccination index (VI) comprising eight standard vaccinations (range 0-1, with higher VI indicating better vaccination coverage). Secondary endpoints included validated measures of general2025-01-01T00:00:00Z20252025-04-05T00:25:53.554Z2025-04-05T00:25:53.554ZS-EPMC117601343986675210.1177/17562864241309806